Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mepartricin→

Mepartricin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
11121-32-7
Molecular formula
C119H174N4O38
Molecular weight
2268.7 g/mol
Drug class
Polyene macrolide antibioticantifungal and antiprotozoal agent
Mechanism of action
A polyene macrolide antibiotic complex derived from Streptomyces aureofaciens. Like other polyenes, it is associated with interaction with sterol-containing biological membranes, although the exact composition and detailed mechanism of mepartricin are not fully characterised.
Indications / reported uses
  • Used in some countries for selected urological indications, including benign prostatic hyperplasia, and historically for antifungal or antiprotozoal purposes; indications and availability vary by jurisdiction.

Sources: https://www.ncbi.nlm.nih.gov/mesh/?term=D008613 · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D008613 · https://www.ncbi.nlm.nih.gov/mesh/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mepartricin Environmental Risk Assessment (ERA) (the Mepartricin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.